Drug Coverage Decision for BC PharmaCare

About PharmaCare BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	glecaprevir-pibrentasvir
Brand name	Maviret®
Dosage forms	100 mg/40 mg (glecaprevir-pibrentasvir) oral tablets, 50 mg/20 mg (glecaprevir-pibrentasvir) oral granules in a sachet
Manufacturer	AbbVie Corporation
Submission type	**New Indication**
Indication reviewed	For the treatment of acute hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing 12 kg or more.
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	The Canadian Drug Expert Committee (CDEC) recommended: **to Reimburse with clinical criteria and/or conditions**. Visit the CDA-AMC website for more details.
Ministry of Health (the Ministry) Review	The Ministry reviewed clinical and pharmacoeconomic combined reports prepared by the CDA-AMC's CRR , including clinical and pharmacoeconomic evidence review material and the recommendations of the CDEC. The Ministry also considered patient input provided to CDEC and a budget impact assessment. The Ministry received two Your Voice patient input questionnaire responses from patient groups, and consultation with specialists.
Drug Coverage Decision	**Limited Coverage benefit**
Date	October 7, 2026
Reasons	Drug coverage decision is consistent with the CDEC recommendation that Maviret be reimbursed by public drug plans for acute HCV infection in adults and in

	pediatric patients aged 3 years and older and weighing 12 kg or more, if certain conditions are met. • Evidence from a clinical trial showed that Maviret given for 8 weeks led to high treatment response and no failure or relapse after treatment in adults with acute HCV infection. However, because the treatment was not compared with anything else, the evidence is uncertain. • CDEC considered that there is a significant unmet clinical need for patients with acute HCV infection and for the broader population at risk of contagion. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review (CRR) process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC's CRR
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug
- the outcomes of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with manufacturers

Visit BC PharmaCare and Drug reviews for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.